Laliberte Kevin

Sr. VP, Product Development at Dova Pharmaceuticals Inc.

Sold, on record
$205k
Dollars the filings state
Form 4 sales
4
Latest Sep 30, 2019
Form 144 notices
0
Proposed sales
Companies
1
Filed as an executive or holder

Companies

Sales by reason

0
Routine
0
Plan not stated
0
No plan
0
Unusual
Stacked: routine sales under a plan, sales whose filing does not state a plan, sales with no plan, and unusual sales.

Form 4 sales per month, last 12 months.

Sales chart range

Timeline

  1. 1 Form 4 sale Dova Pharmaceuticals Inc.Plan not stated
    Jul 1 2019

    Sold 1,191 shares at $14.17 ($17k)

    Laliberte Kevin, Sr. VP, Product Development

    Sold 8.4% of holdings ($200k position)12,946 shares leftFirst sale on recordFiling

  2. 2 Form 4 sale Dova Pharmaceuticals Inc.Plan not stated
    Jul 31 +30 days

    Sold 1,389 shares at $15.97 ($22k)

    Laliberte Kevin, Sr. VP, Product Development

    Sold 10.7% of holdings ($207k position)11,557 shares leftFiling

  3. 3 Form 4 sale Dova Pharmaceuticals Inc.Unusual
    Sep 25 +56 days

    Sold 3,100 shares at $20.00 ($62k)

    Laliberte Kevin, Sr. VP, Product Development

    Sold 26.8% of holdings ($231k position)8,457 shares leftFiling

  4. 4 Form 4 sale Dova Pharmaceuticals Inc.Unusual
    Sep 30 +5 days

    Sold 3,696 shares at $28.00 ($103k)

    Laliberte Kevin, Sr. VP, Product Development

    Sold 43.7% of holdings ($237k position)4,761 shares left2.7x usual sizeFiling

Every transaction

Loading transactions…

Sales and notices (4)

Form 144 notices and Form 4 sales by Laliberte Kevin
Source
Sep 30, 2019Dova Pharmaceuticals Inc.Sr. VP, Product DevelopmentForm 4 sale3,696$103k43.7%UnusualSEC
Sep 25, 2019Dova Pharmaceuticals Inc.Sr. VP, Product DevelopmentForm 4 sale3,100$62k26.8%UnusualSEC
Jul 31, 2019Dova Pharmaceuticals Inc.Sr. VP, Product DevelopmentForm 4 sale1,389$22k10.7%Plan not statedSEC
Jul 1, 2019Dova Pharmaceuticals Inc.Sr. VP, Product DevelopmentForm 4 sale1,191$17k8.4%Plan not statedSEC